

**Disclosure Statement Pursuant to the Pink Basic Disclosure  
Guidelines**

**OTC Pink Basic Disclosure Guidelines**

**BIOTECH MEDICS, INC**  
5850 CANOGA AVE, # 400, WOODLAND HILLS, CALIFORNIA 91367  
800 988-3782  
[www.biotechmedics.co](http://www.biotechmedics.co)  
biotechmedics@gmail.com  
tmiller@biotechmedics.co  
SIC CODE: 2819

**Annual Report**

**For the period ending DECEMBER 31, 2023 (the "Reporting Period")**

**Outstanding Shares**

The number of shares outstanding of our Common Stock was:

202,356,178 as of DECEMBER 31, 2022 (Current Reporting Period Date or More Recent Date)

202,356,178 as of DECEMBER 31, 2023 (Most Recent Completed Fiscal Year End)

**Shell Status**

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

**Change in Control**

Indicate by check mark whether a Change in Control<sup>4</sup> of the company has occurred during this reporting period:

Yes: ☐ No: ☒

---

<sup>4</sup> "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

BIOTECH MEDICS, INC./  
BMCS SUMCOIN INDEX FUND CHANGED 2/17/21  
CHANGED TO BIOTECH MEDICS, INC ON 5-23-2023

Current State and Date of Incorporation or Registration: WYOMING  
Standing in this jurisdiction: (e.g. active, default, inactive): ACTIVE

Prior Incorporation Information for the issuer and any predecessors during the past five years:  
NONE

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

NONE

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

NONE

Address of the issuer's principal executive office:

5850 CANOGA AVE #400 WOODLAND HILLS CALIFORNIA 91367

Address of the issuer's principal place of business:

☐ Check if principal executive office and principal place of business are the same address:

YES

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: ☒ Yes: ☐ If Yes, provide additional details below:

\_\_\_\_\_

**2) Security Information**

**Transfer Agent**

Name: TRANSFER ONLINE  
Phone: 503.227.2950  
Email: CAROLYN@TRANSFERONLINE.COM  
Address: 512 SALMON ST PORTLAND OREGON 97214

**Publicly Quoted or Traded Securities:**

*The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.*

Trading symbol: BMCS  
Exact title and class of securities outstanding: COMMON  
CUSIP: 090699307  
Par or stated value: .001  
Total shares authorized: UNLIMITED DECEMBER 31, 2023  
Total shares outstanding: 202,356,178 DECEMBER 31, 2023  
Total number of shareholders of record: 4,700 DECEMBER 31, 2023

*Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.*

YES

**Other classes of authorized or outstanding equity securities that do not have a trading symbol:**

*The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.*

Exact title and class of the security: PREFERRED  
Par or stated value: .001  
Total shares authorized: 10M as of date: DECEMBER 31, 2023  
Total shares outstanding: 4,043,139 as of date: DECEMBER 31, 2023  
Total number of shareholders of record: 22 as of date: December 31, 2023

*Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.*

\_\_\_\_\_

**Security Description:**

*The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:*

1. **For common equity, describe any dividend, voting and preemption rights.**

ALL COMMON SHARES HAVE 1 FOR 1 VOTING RIGHTS AND NO PREEMPTIVE RIGHTS

2. **For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

SOME PREFERRED SHARES HAVE CONVERSION RIGHTS OF 1000 FOR ONE SHARE OTHERS NONE...  
SHARES BELONGING TO ANTHONY MILLER CEO/PRESIDENT HAVE AN ADDITIONAL 1000 FOR ONE

VOTING RIGHTS AND NO PREFERRED SHARES HAVE PREEMPTIVE RIGHTS. DIRECTS HAVE THE ABILITY TO SET RIGHTS POWERS AND PRIVLEDGES TO PREFERRED SHARES

3. Describe any other material rights of common or preferred stockholders.

NONE

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

NONE

### 3) Issuance History

*The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.*

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

#### A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: ☐ Yes: ☒ (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>12/31/22</u> Common: <u>202,356,178</u> Preferred: <u>0</u> Shares Outstanding as of Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>12/31/22</u> Common: <u>202,356,178</u> Preferred: <u>2,006,501</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.

<u>9/19/2020</u>	<u>New</u>	<u>2M</u>	<u>Preferred</u>	<u>\$.001</u>	<u>No</u>	<u>Anthony Miller</u>	<u>Employment agreement</u>	<u>144</u>	<u>No</u>
<u>10/2/2020</u>	<u>New</u>	<u>6,501</u>	<u>Preferred</u>	<u>\$.001</u>	<u>No</u>	<u>David Adams-838, Daryl Bryant-600, So. Trust (Terrance Dolan)-563, Natasha Mercer-500, Rene Jaegr-2000, Lee Wilson-1500, Sandra Thomas-500</u>	<u>working capital</u>	<u>144</u>	<u>No</u>
<u>03/31/2021</u>	<u>New</u>	<u>6,109</u>	<u>Preferred</u>	<u>\$.01</u>	<u>No</u>	<u>Tamara Farrell-1500, Core Cons (Steven Cass)-3003, William Haramas-1000, David Adams-606</u>	<u>Working capital</u>	<u>144</u>	<u>No</u>
<u>06/30/2021</u> —	<u>NEW</u>	<u>4,003</u>	<u>Preferred</u> —	<u>\$.001</u>	<u>No</u>	<u>Stephanie Hirsch-3003, Scott Benson-1000,</u>	<u>Working capital</u>	<u>144</u>	<u>No</u>
<u>09/30/2021</u> —	<u>NEW</u>	<u>600</u>	<u>Preferred</u> —	<u>\$.001</u>	<u>No</u>	<u>Britt Wilson 600</u>	<u>Working capital</u>	<u>144</u>	<u>No</u>
<u>10/06/21</u>	<u>NEW</u>	<u>1900</u>	<u>Preferred</u>	<u>\$01</u>	<u>No</u>	<u>Britt Wilson 1801</u> <u>David Adams 199</u>	<u>Working Capital</u>	<u>144</u>	<u>No</u>
<u>12/04/21</u>	<u>NEW</u>	<u>1375</u>	<u>Preferred</u>	<u>\$01</u>	<u>No</u>	<u>Paul Mariotta 1250</u> <u>David Adams 125</u>	<u>Working Capital</u>	<u>144</u>	<u>No</u>
<u>09/28/2023</u>	<u>NEW</u>	<u>2 million</u>	<u>Preferred</u>	<u>.01</u>		<u>Rise Defi</u>	<u>Assets to be marketed</u>	<u>144</u>	<u>No</u>
Shares Outstanding on Date of This Report:									
Ending Balance:									
Date <u>12/31/2023</u> Common: <u>202,356,178</u>									
Preferred: <u>4,043,139</u>									

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>12/31/21</u> Common: <u>202,356,178</u> Preferred: <u>0</u> Shares Outstanding as of Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>12/31/22</u> Common: <u>202,356,178</u> Preferred: <u>2,006,501</u>			Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>12/31/21</u> Common: <u>202,356,178</u> Preferred: <u>0</u> Shares Outstanding as of Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>12/31/22</u> Common: <u>202,356,178</u> Preferred: <u>2,006,501</u>			*Right-click the rows below and select "I			
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).
<u>9/19/2020</u>	<u>New</u>	<u>2M</u>	<u>9/19/2020</u>	<u>New</u>	<u>2M</u>	<u>Preferred</u>	<u>\$.001</u>	<u>No</u>	<u>Anthony Miller</u>
<u>10/2/2020</u>	<u>New</u>	<u>6,501</u>	<u>10/2/2020</u>	<u>New</u>	<u>6,501</u>	<u>Preferred</u>	<u>\$.001</u>	<u>No</u>	<u>David Adams-838, Daryl Bryant-600, So. Trust (Terrance Dolan)-563, Natasha Mercer-500, Rene Jaegr-2000, Lee Wilson-1500, Sandra Thomas-500</u>
<u>03/31/2021</u>	<u>New</u>	<u>6,109</u>	<u>03/31/2021</u>	<u>New</u>	<u>6,109</u>	<u>Preferred</u>	<u>\$.01</u>	<u>No</u>	<u>Tamara Farrell-1500, Core Cons (Steven Cass)-3003, William Haramas-1000, David Adams-606</u>
<u>06/30/2021</u> —	<u>NEW</u>	<u>4,003</u>	<u>06/30/2021</u> —	<u>NEW</u>	<u>4,003</u>	<u>Preferred</u> —	<u>\$.001</u>	<u>No</u>	<u>Stephanie Hirsch-3003, Scott Benson-1000,</u>
<u>09/30/2021</u> —	<u>NEW</u>	<u>600</u>	<u>09/30/2021</u> —	<u>NEW</u>	<u>600</u>	<u>Preferred</u> —	<u>\$.001</u>	<u>No</u>	<u>Britt Wilson 600</u>
<u>10/06/21</u>	<u>NEW</u>	<u>1900</u>	<u>10/06/21</u>	<u>NEW</u>	<u>1900</u>	<u>Preferred</u>	<u>\$01</u>	<u>No</u>	<u>Britt Wilson 1801</u>

									David Adams 199
12/04/21	NEW	1375	12/04/21	NEW	1375	Preferred	\$01	No	Paul Mariotta 1250
09/28/2023	NEW	2 million	09/28/2023	NEW	2 million	Preferred	.01		David Adams 125
									Rise Defi
Shares Outstanding on Date of This Report:			Shares Outstanding on Date of This Report:						
Ending Balance:			Ending Balance:						
Date 12/31/2023 Common: 202,356,178			Date 09/30/2023 Common: 202,356,178						
Preferred: 4,043,139			Preferred: 4,043,139						

\*\*\*Control persons for any entities in the table above must be disclosed in the table or in a footnote here.

Use the space below to provide any additional details, including footnotes to the table above:

N/A

## B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: ☒ Yes: ☐ (If yes, you must complete the table below)

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder. *** You must disclose the control person(s) for any entities listed.	Reason for Issuance (e.g. Loan, Services, etc.)
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

\*\*\*Control persons for any entities in the table above must be disclosed in the table or in a footnote here.

Use the space below to provide any additional details, including footnotes to the table above:

NONE

#### 4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on [www.OTCMarkets.com](http://www.OTCMarkets.com).

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

BioTech Medics, Inc. formerly BMCS SUMCOIN INDEX FUND is a medical holding company that is engaged in provisional medical services that have a progressive business plan. The company has legacy patented technologies (for retail applications) that will be further developed and an even broader range of new products that will be disclosed throughout 2020 and beyond. Company's divisions were Medical, Nutraceutical Products, Sports Medicine and Research & Development. These divisions all have products produced for their target audience.

On May 23, 2023, management (after over 2 years trying to get our name change through FINRA) decided to abandon the name change and the digital asset business plan. Management decided to take the Company back to its biotech roots and did initiate an agreement with certain asset holders in the Dominican Republic with Calcium carbonate reserves. On September 28, 2023 as a result of a negotiated agreement BioTech Medics received 2 million metric tons of very high quality (99.8% pure) calcium carbonate to market to a worldwide marketplace. This calcium carbonate has a base value of \$30 million dollars (2 million tons @ \$15.00 per ton). As management goes into the sales portals it is common that this same calcium carbonate (request for proposals-RFP) has common requested values in excess of \$85.00 per metric ton (in the portals). Further note that this was a significant transaction that management negotiated for the firm since the assets were acquired for 2 million Series A preferred shares of stock.

Finally, management did procure (along with this transaction) an option to acquire an additional 48 million metric tons of calcium carbonate at a similar transaction value. Our new business plan is an old school commodities plan where we mine our calcium... put in on a truck and then put it on a ship to send it to the client. This business model has traditional profit margins in excess of 33% per transaction. Management is currently working on a number of marketing strategies to market this enormous calcium asset that will include online sales, apps, blockchains and is working on a calcium exchange to market our assets to the world.

**About Calcium Carbonate:** *The global calcium carbonate market size was valued at USD 44.7 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 6.6% from 2023 to 2030. Increasing demand for paper from packaging applications and hygiene-related products like tissue paper is a significant growth driver. The U.S. has been a prominent destination for the product considering high demand from industries. Paper is the largest application segment of the market, and the U.S. is among the world's largest paper manufacturers.*

*Calcium carbonate is also used as organic fertilizer, to produce calcium citrate (citric acid), which is used as a food additive, a preservative, an acidifier, or a flavouring agent. It is used in applications such as cleaning agents, cosmetics, pharmaceuticals, and dietary supplements. As utilized in building material, it helps to manufacture mortar that holds together tiles, rubber products, roofing tiles, concrete slabs and stones and is employed in paints and pigments. Additionally, baking powder, wine, dough, plastics, adhesives sealants and more. It is also used to adjust the pH value of water through the neutralization process. Calcium is a widely utilized commodity with tremendous applications*

**BIOTECH MEDICS IS NOT A FINANCIAL SERVICES COMPANY AND THE FIRM HAS DIGITAL ASSETS ON ITS BALANCE SHEET HOWEVER, THE FIRM IS NOT A DIGITAL ASSET COMPANY AND DOES NOT SELL OR TRADE DIGITAL ASSETS... AND INVESTORS SHOULD NOT UTILIZE THE COMPANIES DIGITAL ASSETS FOR INVESTING DECISION INTO THIS COMPANY.**

B. List any subsidiaries, parent company, or affiliated companies.

None

C. Describe the issuers' principal products or services.

Calcium is also used as organic fertilizer, to produce calcium citrate (citric acid), which is used as a food additive, a preservative, an acidifier, or a flavouring agent. It is used in applications such as cleaning agents, cosmetics, pharmaceuticals, and dietary supplements. As utilized in building material, it helps to manufacture mortar that holds together tiles, rubber products, roofing tiles, concrete slabs and stones and is employed in paints and pigments. Additionally, baking powder, wine, dough, plastics, adhesives sealants and more. It is also used to adjust the pH value of water through the neutralization process. Calcium is a widely utilized commodity with tremendous applications.

## 5) Issuer's Facilities

*The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.*

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Company executive offices are located at 5850 Canoga Ave #400 Woodland Hills, Ca. 91367 our offices are in a high rise building and our space (executive suite) in this facility provides us with 10 hours monthly conference space and 24 hour office access

## 6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

*The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.*

Names of All Officers, Directors, and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of 5% or more)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
<u>Anthony Miller</u>	<u>67% by proxy</u>	<u>West Hills Ca</u>	<u>154m</u> <u>2m</u>	<u>Common</u> <u>Preferred</u>	<u>67%</u>	<u>N/A</u>
<u>BioTech Medics Trust</u>	<u>67%</u> Anthony Miller	<u>N/A</u>	<u>154m</u>	<u>Common</u>	<u>67%</u>	<u>Anthony Miller</u>

<u>David Adams</u>	<u>&lt;.01%</u>	<u>Moreno Valley, Ca</u>	<u>2m</u>	<u>preferred</u>	<u>&lt;.01</u>	<u>_____</u>
<u>Natasha Mercer</u>	<u>&lt;.01</u>	<u>Santa Clarita, ca</u>	<u>500</u>	<u>preferred</u>	<u>&lt;.01</u>	<u>_____</u>
<u>Melanie Dixon</u>	<u>0</u>	<u>Santa Clarita, Ca</u>	<u>0</u>	<u>N/A</u>	<u>0</u>	<u>_____</u>

Confirm that the information in this table matches your public company profile on [www.OTCMarkets.com](http://www.OTCMarkets.com). If any updates are needed to your public company profile, log in to [www.OTCIQ.com](http://www.OTCIQ.com) to update your company profile.

## 7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

None

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

## 8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on [www.OTCMarkets.com](http://www.OTCMarkets.com). If any updates are needed to your public company profile, update your company profile.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name: Thomas C. Cook  
Firm:  
Address 1: Las Vegas, Nevada 89129  
Address 2:  
Phone: 702.524.9151  
Email: tccesq@aol.com

### Accountant or Auditor

Name:  
Firm: Heaton & Company, PLLC  
Address 1: 1438 N. Highway 89  
Address 2: # 120 Farmington UT. 84025  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

### Investor Relations

Name:  
Firm:  
Address 1:  
Address 2:  
Phone:  
Email:

*All other means of Investor Communication:*

X (Twitter): @biotechmedics  
Discord: N/A  
LinkedIn: BioTech Medics  
Facebook: N/A  
[Other ] N/A

### Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: None  
Firm: \_\_\_\_\_  
Nature of Services: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

## 9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Anthony K. Miller  
Title: President/CEO  
Relationship to Issuer: President/CEO

B. The following financial statements were prepared in accordance with:

☐ IFRS  
☒ U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Anthony Miller  
Title: \_\_\_\_\_  
Relationship to Issuer: \_\_\_\_\_

Describe the qualifications of the person or persons who prepared the financial statements:<sup>5</sup> \_\_\_\_\_

Provide the following qualifying financial statements:

- ☐ Audit letter, if audited;
- ☐ Balance Sheet;
- ☐ Statement of Income;
- ☐ Statement of Cash Flows;
- ☐ Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- ☐ Financial Notes

---

<sup>5</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

**BIO TECH MEDICS, INC.**  
**BALANCE SHEET**  
**FOR THE YEARS ENDED DECEMBER 31, 2023 & DECEMBER 31, 2022**

	<u>Dec 31, 2023</u>	<u>Dec 31, 2022</u>
<b>ASSETS</b>		
Current Assets		
Cash	\$ 102	\$ (726)
Total Current Assets	102	(726)
Fixed Assets		
Equipment	1,366,908	1,366,908
Furniture & Fixtures	372	372
Accumulated Depreciation	(1,380,157)	(1,380,157)
Total Fixed Assets, Net	(12,876)	(12,876)
Intangible Assets		
BioBody	5,000,000	5,000,000
US Patents SHBAN	1,250,000	1,250,000
Research & Development	15,250	15,250
Accumulated Amortization	(6,250,000)	(6,250,000)
Total Intangible Assets, Net	15,250	15,250
Other Assets		
Investment in Calcium Carbonate	30,000,000	
Investment in Digital Currency	70,000,000	70,000,000
Total Other Assets	100,000,000	70,000,000
<b>TOTAL ASSETS</b>	<u><u>\$ 100,002,477</u></u>	<u><u>\$ 70,001,648</u></u>
<b>LIABILITIES &amp; STOCKHOLDERS' EQUITY</b>		
Liabilities		
Current Liabilities		
Accounts Payable	\$ 39,528	\$ 62,833
Accrued Interest	\$ 1,050	
Employment Accrual - Related Party	358,920	357,614
Other Current Liabilities	5,286	5,286
S-T Note	27,000	
Total Current Liabilities	431,784	425,733
Total Liabilities	\$ 431,784	\$ 425,733
Stockholders' Equity		
<b>Series A Preferred Stock</b> - Par Value		
\$0.001 5,000,000 authorized, 4,043,139	4,076	2,076
issued and outstanding		
<b>Common Stock</b> - \$0.001 Par Value		
500,000,000 shares authorized,	202,356	202,356
202,356,178 shares issued and		
Additional Paid In Capital	101,021,995	71,023,995
Accumulated Deficit	(1,657,734)	(1,651,786)
Total Stockholders' Deficit	99,570,693	69,576,641
<b>D. TOTAL LIABILITIES &amp; STOCKHOLDERS' EQUITY</b>	<u><u>\$ 100,002,477</u></u>	<u><u>\$ 70,002,374</u></u>

**BIO TECH MEDICS, INC.**  
**STATEMENT OF OPERATIONS**  
**FOR THE YEARS ENDED DECEMBER 31, 2023 & DECEMBER 31, 2022**

	Dec 31, 2023	Dec 31, 2022
REVENUE	<u>\$ -</u>	<u>\$ -</u>
EXPENSES		
Salaries & Wages - Related Party		80,000
General & Administrative	<u>4,687</u>	<u>34,821</u>
Total Expense	<u>4,687</u>	<u>114,821</u>
OTHER INCOME (EXPENSE)		
Gain on Settlement of Debt		
Other Income	<u>22,700</u>	
Total Other Income (Expense)	<u>22,700</u>	<u>-</u>
NET INCOME (LOSS)	<u>\$ 18,013</u>	<u>\$ (114,821)</u>
Basic & Diluted Weighted Average Common Shares Outstanding	202,356,178	202,356,178
E. Basic & Diluted Loss Per Share	\$ 0.00	\$ (0.00)

**BIO TECH MEDICS, INC.**  
**STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY**  
**FOR THE YEARS ENDED DECEMBER 31, 2023 & DECEMBER 31, 2022**

	Common Stock		Preferred Stock		Paid In Capital	Accumulated Deficit	Total
	Shares	Amount	Shares	Amount			
Balance 12/31/22	<u>202,356,178</u>	<u>202,356</u>	<u>2,043,139</u>	<u>2,076</u>	<u>71,023,995</u>	<u>(1,652,111)</u>	<u>69,576,316</u>
Net Loss						(2,406)	(2,406)
Balance 3/31/23	<u>202,356,178</u>	<u>202,356</u>	<u>2,043,139</u>	<u>2,076</u>	<u>71,023,995</u>	<u>(1,654,517)</u>	<u>69,573,910</u>
Net Loss						(14,699)	(14,699)
Balance 6/30/23	<u>202,356,178</u>	<u>202,356</u>	<u>2,043,139</u>	<u>2,076</u>	<u>71,023,995</u>	<u>(1,669,216)</u>	<u>69,559,211</u>
Issued Preferred Stock for Calcium Carbonate			2,000,000	2,000	29,998,000		30,000,000
Net Loss						(6,531)	(6,531)
Balance 9/30/23	<u>202,356,178</u>	<u>202,356</u>	<u>4,043,139</u>	<u>4,076</u>	<u>101,021,995</u>	<u>(1,675,747)</u>	<u>99,552,680</u>
Net Loss						18,013	18,013
G. Balance 12/31/23	<u>202,356,178</u>	<u>202,356</u>	<u>4,043,139</u>	<u>4,076</u>	<u>101,021,995</u>	<u>(1,657,734)</u>	<u>99,570,693</u>

**BIO TECH MEDICS, INC.**  
**STATEMENT OF CASH FLOWS**  
**FOR THE YEARS ENDED DECEMBER 31, 2023 & DECEMBER 31, 2022**

	<u>Dec 31, 2023</u>	<u>Dec 31, 2022</u>
<b>OPERATING ACTIVITIES</b>		
Net Income	\$ (5,624)	\$ (114,821)
Adjustments to reconcile net loss to net cash provided by (used in) operations:		
Depreciation		
Gain on Settlement of Debt		
Accounts Payable	(23,630)	16,424
Accrued Interest	1,050	
Employment Accrual - Related Party	1,306	76,060
Other Current Liabilities	-	5,562
S-T Note	27,000	
Net cash provided by (used in) Operating Activities	<u>102</u>	<u>(16,774)</u>
<b>INVESTING ACTIVITIES</b>		
Purchase of Furniture & Fixtures	-	
Investment in Calcium Carbonate	(30,000,000)	
Investment in Digital Currency	-	
Net cash provided by (used in) Investing Activities	<u>(30,000,000)</u>	<u>-</u>
<b>FINANCING ACTIVITIES</b>		
Additional Paid In Capital	29,998,000	
Proceeds from Issuance of Preferred Stock	2,000	17,500
Net cash provided by Financing Activities	<u>30,000,000</u>	<u>17,500</u>
 Net cash increase (decrease) for period	 102	 726
 Cash at beginning of period	 -	 (726)
 Cash at end of period	 <u>\$ 102</u>	 <u>\$ -</u>
 <b>SUPPLEMENTAL CASH FLOW INFORMATION</b>		
 Interest Paid	 \$ -	 \$ -
I. Income Taxes Paid	\$ -	\$ -

**J. Financial Statement Requirements:**

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be “machine readable”. Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

**10) Issuer Certification**

*Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Anthony K. Miller certify that:

1. I have reviewed this Disclosure Statement for BioTech Medics Inc;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

March 14, 2024 [Date]

//Anthony K. Miller [CEO's Signature]

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)

*Principal Financial Officer:*

I, Anthony K. Miller certify that:

1. I have reviewed this Disclosure Statement for BioTech Medics Inc
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

March 14, 2024 [Date]

//Anthony K. Miller [CFO's Signature]

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)

**Notes to Financial Statements  
For the Quarter Ended December 31, 2023  
Annual Report**

**NATURE OF OPERATIONS**

**NOTE: 1 - HISTORY OF COMPANY**

BioTech Medics, Inc. (The Company) was formed on December 29, 1997 to operate as a property owner and/or management service. On December 7, 2004, the Company acquired Halo Laser BioTherapy, LLC via a reverse merger which focused on alternative medicine, nutraceuticals, alcohol free hand sanitizer and high-powered deep penetrating laser medical devices for the twenty-first century. On November 6, 2007, the Company submitted documents with the secretary of state in Nevada to change the Company's name to BioTech Medics, Inc. and continued with limited operations until 2019

On June 6, 2019, Anthony K. Miller was appointed as the new Chairman and CEO of BioTech Medics, Inc., a Wyoming corporation. On June 18, 2019, the Secretary of State amended the corporation's records to reflect the change of officers. BioTech Medics, Inc is a publicly traded company on the OTC Market and trades under the stock symbol BMCS.

Prior to November 2020, BioTech Medics, Inc. was engaged in provisional medical services. BioTech Medics, Inc. In 2021 management changed its business model to a digital asset business and built significant business architecture with new websites, currency, podcast, a news channel and a team to conduct that business mode. Management entered into a name change of the company to BMCS SUMCOIN INDEX FUND. However, the regulatory climate was not amenable to the company's business model (an Index Fund) and set roadblocks to delay the Company's name change. The name change was important because it reflected the business mode and that (in flux) name change also stalled the company from elevating to an OTCQB firm.

On May 23, 2023, management (after over 2 years trying to get our name change through FINRA) decided to abandon the name change and the digital asset business plan. Management decided to take the Company back to its biotech roots and did initiate an agreement with certain asset holders in the Dominican Republic with Calcium carbonate reserves. On September 28, 2023 as a result of a negotiated agreement BioTech Medics received 2 million metric tons of very high quality (99.8% pure) calcium carbonate to market to a worldwide marketplace. This calcium carbonate has a base value of \$30 million dollars (2 million tons @ \$15.00 per ton). As management goes into the sales portals it is common that this same calcium carbonate (request for proposals-RFP) has common requested values in excess of \$85.00 per metric ton (in the portals). Further note that this was a significant transaction that management negotiated for the firm since the assets were acquired for 2 million Series A preferred shares of stock. Finally, management did procure (along with this transaction) an option to acquire an additional 48 million metric tons of calcium carbonate at a similar transaction value. Our new business plan is an old school commodities plan where we mine our calcium... put in on a truck and then put it on a ship to send it to the client. This business model has traditional profit margins in excess of 33% per transaction.

Management is currently working on several marketing strategies to market this enormous calcium asset that will include online sales, apps, blockchains and is working on a calcium exchange to market our assets to the world. Additional information about the company and its business plan can be found on the company's website @ [www.biotechmedics.co](http://www.biotechmedics.co)

***About Calcium Carbonate:***

*Calcium carbonate is also used as organic fertilizer, to produce calcium citrate (citric acid), which is used as a food additive, a preservative, an acidifier, or a flavouring agent. It is used in applications such as cleaning agents, cosmetics, pharmaceuticals, and dietary supplements. As utilized in building material, it helps to manufacture mortar that holds together tiles, rubber products, roofing tiles, concrete slabs and stones and is employed in paints and pigments. Additionally, baking powder, wine, dough, plastics, adhesives sealants and more. It is also used to adjust the pH value of water through the neutralization process. Calcium is a widely utilized commodity with tremendous applications*

***BIOTECH MEDICS IS NOT A FINANCIAL SERVICES COMPANY AND THE FIRM HAS DIGITAL ASSETS ON ITS BALANCE SHEET HOWEVER, THE FIRM IS NOT A DIGITAL ASSET COMPANY AND DOES NOT SELL OR TRADE DIGITAL ASSETS... AND INVESTORS SHOULD NOT UTILIZE THE COMPANIES DIGITAL ASSETS FOR INVESTING DECISION INTO THIS COMPANY.***

## **NOTE 2 – GOING CONCERN**

The Company currently has limited working capital and has not completed its efforts to establish a stabilized source of revenue sufficient to cover operating costs over an extended period of time. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses. The Company intends to position itself to raise additional funds through the capital markets. In light of management's efforts, there are no assurances that the Company will be successful in this or any of its endeavours to become financially viable. As reflected in the financial statements, the Company has some working capital for the period ended December 31, 2023, and a loss from operations. The Company is working on raising significant capital that is non-dilutive to be able to execute its current business plan. The accompanying financial statements have been prepared by management assuming the Company will continue in its efforts.

## **NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

### ***Basis of Presentation***

The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles.

### ***Use of Accounting Estimates***

Management is required to make estimates and assumptions during the preparation of the financial statements and accompanying notes in conformity with accounting principles generally accepted in the United States of America. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements. They also affect the reported amounts of net income. Actual results could differ materially from these estimates and assumptions.

### ***Cash and Cash Equivalents***

The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.

### ***Fixed Assets***

Equipment is stated at cost, net of accumulated depreciation. The cost of equipment is depreciated using the straight-line method. We estimate that the useful life of equipment is 5 years. Expenditures for maintenance and repairs are charged to expense as incurred. Additions, major renewals, and replacements that increase the equipment's useful life are capitalized. Equipment sold or retired, together with the related accumulated depreciation is removed from the appropriated accounts and the resultant gain or loss is included in net income.

### ***Digital Assets***

Guidance on how to account for and audit digital assets under U.S. generally accepted accounting principles (GAAP) for nongovernmental entities and generally accepted auditing standards (GAAS), respectively. This guidance is intended for financial statement preparers and auditors with a fundamental knowledge of blockchain technology. For the purposes of this practice aid, digital assets are defined broadly as digital records that are made using cryptography for verification and security purposes, on a distributed ledger (referred to as a blockchain). The distributed ledger keeps a record of all transactions on a blockchain network. Digital assets, as defined herein, may be characterized by their ability to be used for a variety of purposes, including as a medium of exchange, as a representation to provide or access goods or services, or as a financing vehicle, such as a security, among other uses. The rights and obligations associated with digital assets vary significantly, as do the terms used to describe them. It is important to note that the accounting treatment for a digital asset will ultimately be driven by the specific terms, form, underlying rights, and obligations of the digital asset.

BIOTECH MEDICS IS NOT A FINANCIAL SERVICES COMPANY AND THE FIRM HAS DIGITAL ASSETS ON ITS BALANCE SHEET HOWEVER, THE FIRM IS NOT A DIGITAL ASSET COMPANY AND DOES NOT SELL OR TRADE OR SUGGEST ANY DIGITAL ASSETS AT THIS MOMENT... AND INVESTORS SHOULD NOT UTILIZE THE COMPANIES DIGITAL ASSETS FOR INVESTING DECISION INTO THIS COMPANY. IT IS MANAGEMENT'S OBJECTIVE TO LIQUIDATE THIS CURRENCY THROUGH A TRADE OR OTHER TRANSACTION BENEFICIAL TO THE FIRM... SUMCOIN IS IN NO WAY APART OF THE VISION OF THIS FIRM (FROM A BUSINESS MODEL STANDPOINT). MANAGEMENT HAS NO CONFIDENCE THAT THIS CURRENCY WILL BECOME LIQUID SUFFICIENT TO BE UTILIZED FOR ITS OPERATION.... IT WILL REMAIN IT AS AN INTANGIBLE ASSET ON THE COMPANY'S BALANCE SHEET FOR THE NEAR FUTURE. MANAGEMENT DOES BELIEVE IN BLOCKCHAIN PRODUCTS AND SERVICES... AND THE FIRM WILL ENDEAVOR TO BECOME ACTIVE IN THIS EMERGING GROWTH MARKETPLACE IN 2024 AND MAY DEVELOPE PROJECTS THAT ENCORPORATE THIS THECNOLOGY.

### ***About the Calcium Carbonate Industry:***

*The global calcium carbonate market size was valued at USD 44.7 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 6.6% from 2023 to 2030. Increasing demand for paper from packaging applications and hygiene-related products like tissue paper is a significant growth driver. The U.S. has been a prominent destination for the product considering high demand from industries. Paper is the largest application segment of the market, and the U.S. is among the world's largest paper manufacturers.*

### ***Goodwill and Other Intangible Assets***

The Company accounts for goodwill and other intangible assets in accordance with ASC 350, "Intangibles - Goodwill and Other". Intangible assets with an indefinite life, namely goodwill, are not amortized. Intangible assets with a definite life are amortized on a straight-line basis over their estimated useful lives of seventeen years. Intangible assets with indefinite lives will be tested for impairment annually and when an event occurs that would indicate that the carrying amount may be impaired.

### ***Impairment of Assets***

In accordance with ASC 350 "Intangibles – Goodwill and Other" and ASC 360 "Property, Plant and Equipment," long-lived assets, such as property and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When factors indicate that the assets should be evaluated for possible impairment, the Company uses an estimate of related cash flows. A deficiency in these cash flows relative to the carrying amounts is an indication of the need for a write-down due to impairment. Losses on impairment are recognized by a charge to earnings.

### ***Income Taxes***

Income taxes are computed using the asset and liability method in accordance with ASC 740 "Income Taxes." Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

### ***Fair Value of Financial Instruments***

The Company, in estimating its fair value disclosures for financial instruments, uses the following methods and assumptions: The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate their fair value due to their relatively short maturity.

### ***Basic Income (Loss) Per Share***

The Company computes income (loss) per share in accordance with FASB ASC 260 "Earnings per Share." Basic loss per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted income (loss) per share gives effect to all dilutive potential common shares outstanding during the

period. Dilutive loss per share excludes all potential common shares if their effect is antidilutive. There are potentially dilutive debt or equity instruments issued or outstanding as of December 31, 2023, upon conversion of preferred shares into common shares.

### ***Recent Accounting Pronouncements***

We have reviewed all the recently issued, but not yet effective, accounting pronouncements and we do not believe any of these pronouncements will have a material impact on the Company.

### **NOTE 4 – STOCKHOLDERS’ EQUITY**

The Company has authorized an unlimited number of shares at a \$0.001 par value shares of common stock, and 202,356,178 common shares issued and outstanding as of December 31, 2023. During the period ended December 31, 2023, the Company did not issue Series A preferred shares to certain shareholders for cash to be used as working capital. Collectively as of December 31, 2023 the Company has 79,775 total digital currencies whose value at this date was approximately \$70 million based upon the Sumcoin closing price on December 31, 2021 of \$979.04 per coin. As of the date of this filing the Sumcoin value has fallen to approximately \$655.32. Note: the coin’s value changes every 20 minutes. There are 10 million authorized preferred shares (par value .001) including 5 million Series A, and 5 million Series B shares. Management has the authority to set the rights powers and privileges to these shares.

### **NOTE 5- RELATED PARTY TRANSACTIONS**

The employment agreement for Anthony Miller, Chief Executive Officer, entered into on June 27, 2019, comprises the balance of the employment accrual – related party. Mr. Miller is entitled to compensation of \$120,000 per year for a period of five years. The balance owed to Mr. Miller as of December 31, 2021 was \$281,277. As of December 31, 2023, the balance is \$358,920. During this quarter management did authorize the issuance of shares of preferred shares to certain directors as part of the Company’s Employee stock option plan authorized in 2021 such share shall be subject to traditional 144 holding and reporting rules.

### **NOTE 6 – INCOME TAXES**

The Company adopted the provisions of uncertain tax positions as addressed in ASC 740 “Income Taxes” (“ASC 740”). As a result of the implementation of ASC 740, the Company recognized no increase in the liability for unrecognized tax benefits. As of December 31, 2023, the Company had net operating loss carry forwards of approximately \$1,657,734 that may be available to reduce future years’ taxable income in varying amounts. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards.

As of December 31, 2023, the valuation allowance was approximately \$ 257,196. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all the deferred income tax assets will not be realized.

The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of December 31, 2022. All tax years since 2017 remain open for examination by taxing authorities.

The provision for Federal income tax consists of the following:

	December 31, 2020	December 31, 2021
Federal income tax benefit attributable to:		

Income tax benefit	\$	23,030	23,030
Change in valuation allowance		(23,030)	(23,030)
Net provision for Federal income taxes	\$	-	-

The cumulative tax effect at the expected rate of 21% of significant items comprising our net deferred tax amount is as follows:

	December 31, 2020	December 31, 2021
Deferred tax asset attributable to:		
Net operating loss carryover	\$ 255,025	231,995
Less: valuation allowance	(255,025)	(231,995)
Net deferred tax asset	\$ -	-

The related deferred tax benefit on the above unutilized tax losses has a full valuation allowance not recognized against it as there is no certainty of its realization. Management has evaluated tax positions in accordance with ASC 740 and has not identified any significant tax positions, other than those disclosed.

#### **NOTE 7 – GAIN ON SETTLEMENT OF DEBT**

During the year ended December 31, 2020, the Company had an outstanding balance of \$54,558 with its transfer agent. The Company negotiated a settlement with the transfer agent and paid \$10,000 and the remaining \$44,558 was forgiven by the transfer agent and recorded as a gain on settlement of debt.

#### **NOTE 8 – SUBSEQUENT EVENTS**

In accordance with ASC 855 “*Subsequent Events*,” the Company has analysed its operations subsequent to December 31, 2021, through the date these financial statements were issued and has determined that it has no material subsequent events requiring disclosure